Press Room

The CMTA’s new $200K+ investment accelerates CMT1A organoid research, revolutionizing treatment evaluation for Charcot-Marie-Tooth disease (CMT) GLENOLDEN, PENNSYLVANIA, USA, February 21, 2024 — The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research ...

It is with the heaviest of hearts that the Charcot-Marie-Tooth Association (CMTA) mourns the loss of our friend and Strategy to Accelerate Research (STAR) Scientific Advisory Board (SAB) Member, Dr. M. Laura Feltri. Dr. Feltri ...

In a recent announcement, Vanda Pharmaceuticals Inc. shared that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its VCA-894A compound. This approval marks a significant step forward ...

In a statement released on February 15, 2024, by Charcot-Marie-Tooth Association (CMTA) Alliance Partner, Applied Therapeutics, the company said that its INSPIRE Phase III trial for a certain type of Charcot-Marie-Tooth disease (CMT), called SORD-deficiency, ...

The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research that’s aimed at bringing treatments and a cure to patients of this rare disease, is pleased to announce the appointment of Dr. ...